We have previously proposed the development of multi-targeting agents for Aβ plaque removal in AD, which would comprise an Aβ-plaque-targeting agent that is tethered to a second target agent, P-glycoprotein (Pgp), to assist in the removal of the plaque components from the brain and the surrounding vasculature across the blood–brain barrier (BBB), as shown in Figure 1 [7]. Here, PGP is linked to Alzheimer disease.